Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)

被引：55

作者：

Bang, Y.

Kwak, E. L.

Shaw, A. T.

Camidge, D. R.

Iafrate, A. J.

Maki, R. G.

Solomon, B. J.

Ou, S. I.

Salgia, R.

Clark, J. W.

机构：

[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Univ Colorado Denver, Aurora, CO USA

[4] Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[7] Canc Trials Australia, Melbourne, Vic, Australia

[8] Univ Calif Irvine, Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[9] Univ Chicago, Dept Med, Chicago, IL 60637 USA

[10] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.18_suppl.3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1